Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-084 manufacturers

Filters

1 products found

pp-084

Solution for infusion

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Advanced solid tumors and hematologic malignancies dependent on anti-apoptotic BCL-2 family signaling, including small cell lung cancer (SCLC), non–small cell lung cancer (NSCLC), and other apoptosis-resistant tumors. Clinical stage: Phase I/II clinical development in multiple tumor settings, evaluating both monotherapy and combination regimens. Modality: Small-molecule targeted therapy Mechanism / Target: Dual inhibitor selectively targeting BCL-2 and BCL-XL to restore apoptotic activity in cancer cells by disrupting survival signaling pathways. Route / form: Intravenous formulation Differentiation: Engineered to balance potent BCL-2/BCL-XL inhibition while potentially reducing dose-limiting thrombocytopenia commonly associated with BCL-XL blockade; early clinical data support antitumor activity in apoptosis-driven cancers with a tolerability profile favorable for combination strategies.
Manufacturer #38620

A global, clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule therapies addressing unmet needs in hematological cancers and other serious diseases. It advances programs through international registrational trials with strategic development and partnership goals. The organization integrates R&D and global expansion efforts.
 

 

 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.